Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension

被引：52
|
作者：
Halank, M [1 ]
Miehlke, S [1 ]
Hoeffken, G [1 ]
Schmeisser, A [1 ]
Schulze, M [1 ]
Strasser, RH [1 ]
机构：
[1] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Internal Med, D-8027 Dresden, Germany
来源：
TRANSPLANTATION | 2004年 / 77卷 / 11期
关键词：
D O I：
10.1097/01.TP.0000122420.86904.89
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：1775 / 1776
页数：2
相关论文
共 50 条
  • [1] Endothelin-Receptor Antagonist Treatment of Portopulmonary Hypertension
    Hinterhuber, Lukas
    Graziadei, Ivo W.
    Kaehler, Christian M.
    Jaschke, Werner
    Vogel, Wolfgang
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (11) : 1039 - 1042
  • [2] The endothelin-receptor antagonist bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects
    Sitbon, O
    Beghetti, M
    Petit, J
    Iserin, L
    Humbert, M
    Gressin, V
    Simonneau, G
    [J]. EUROPEAN HEART JOURNAL, 2004, 25 : 22 - 22
  • [3] The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension
    Krum, H
    Viskoper, RJ
    Lacourciere, Y
    Budde, M
    Charlon, V
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (12): : 784 - 790
  • [4] Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension
    Galiè, N
    Hinderliter, AL
    Torbicki, A
    Fourme, T
    Simonneau, G
    Pulido, T
    Espinola-Zavaleta, N
    Rocchi, G
    Manes, A
    Frantz, R
    Kurzyna, M
    Nagueh, SF
    Barst, R
    Channick, R
    Dujardin, K
    Kronenberg, A
    Leconte, I
    Rainisio, M
    Rubin, L
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (08) : 1380 - 1386
  • [5] Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats
    Chen, SJ
    Chen, YF
    Meng, QC
    Durand, J
    Dicarlo, VS
    Oparil, S
    [J]. JOURNAL OF APPLIED PHYSIOLOGY, 1995, 79 (06) : 2122 - 2131
  • [6] Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin
    Weber, C
    Banken, L
    Birnboeck, H
    Schulz, R
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (08): : 847 - 854
  • [7] Treatment of pulmonary arterial hypertension (PAH) with oral endothelin-receptor antagonist bosentan in systemic sclerosis: BREATHE-1 trial and clinical experience
    Ahmadi-Simab, K
    Lamprecht, P
    Hellmisch, B
    Gross, WL
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2004, 63 (06): : 495 - 497
  • [8] Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects
    Weber, C
    Schmitt, R
    Birnboeck, H
    Hopfgartner, G
    vanMarle, SP
    Peeters, PAM
    Jonkman, JHG
    Jones, CR
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (02) : 124 - 137
  • [9] Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxentan
    Kaehler, Christian M.
    Graziadei, Ivo
    Vogelsinger, Helene
    Desole, Susanna
    Cima, Katharina
    Vogel, Wolfgang
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2011, 123 (7-8) : 248 - 252
  • [10] Aprocitentan (a Dual Endothelin-Receptor Antagonist) for Treatment-Resistant Hypertension
    McCoy, Emily K.
    Lisenby, Katelin M.
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2021, 77 (06) : 699 - 766
12345